NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2023-12-20 | Pages: 200+ | Report ID: MD-R-2023-12-20-199697 | Healthcare
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Next Generation Diabetes Therapy and Drug Delivery Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET
7.1 GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 Abbott Laboratories
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Medtronic, Inc.
16.3 Sanofi
16.4 Novo Nordisk
16.5 MannKind Corporation
16.6 Enteris BioPharma
16.7 Dexcom, Inc.
16.8 Senseonics Holding, Inc.
16.9 Medtech
16.10 Johnson & Johnson
16.11 Synertech
16.12 Zosano Pharma Corp
16.13 Relmada Therapeutics
16.14 Eli Lilly and Company
16.15 Transdermal Specialties Inc
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By Product TypeInhalable Insulin
Oral Insulin
Insulin Patches
CGM Systems
Artificial Pancreas
By Demographic
Adult Population (>14years)
Child Population (14years)
By Indication
Type 1 Diabetes
Child Population (14years)
By End User
Diagnostic/Clinics
ICUs
Home Healthcare
Companies
Abbott Laboratories
Medtronic, Inc.
Sanofi
Novo Nordisk
MannKind Corporation
Enteris BioPharma
Dexcom, Inc.
Senseonics Holding, Inc.
Medtech
Johnson & Johnson
Synertech
Zosano Pharma Corp
Relmada Therapeutics
Eli Lilly and Company
Transdermal Specialties Inc
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.